Modafinil Generics [uk] Limited

Modafinil, the active ingredient in Modafinil Generics [uk] Limited, is a eugeroic presented as an oral tablet for oral use. It promotes wakefulness in adults with excessive daytime sleepiness due to narcolepsy, obstructive sleep apnea, or shift work disorder.

GNH USA supplies Modafinil Generics [uk] Limited as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Modafinil is indicated for disorders that cause excessive daytime sleepiness and affect wakefulness pathways. - Narcolepsy: reduces daytime sleepiness and improves alertness. - Obstructive sleep apnea (in conjunction with primary therapy): lessens residual sleepiness. - Shift work disorder: helps maintain alertness during scheduled work hours.

Modafinil may cause a range of adverse reactions, from mild to serious.

Common Side Effects: - Headache: mild to moderate intensity. - Nausea: occasional gastrointestinal upset. - Insomnia: difficulty initiating or maintaining sleep. - Anxiety: feelings of nervousness or tension. - Dry mouth: reduced salivation. - Dizziness: light‑headed sensation.

Serious or Rare Side Effects: - Severe rash or Stevens‑Johnson syndrome. - Psychiatric symptoms such as hallucinations or mania. - Cardiovascular events including hypertension or arrhythmia. - Hepatic dysfunction: elevated liver enzymes. - Anaphylaxis: acute allergic reaction requiring emergency care.

Before initiating therapy, consider the following safety measures. - Cardiovascular assessment: evaluate blood pressure and heart disease history. - Psychiatric history: screen for pre‑existing mental health conditions. - Liver function: check hepatic enzymes in patients with liver impairment. - Drug dependence: avoid in individuals with a history of substance abuse. - Pregnancy and lactation: use only if the potential benefit outweighs risk. - Store at room temperature below 25°C: keep in the original pack, protect from moisture and light.

Modafinil can interact with several medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase modafinil plasma levels. - Serotonergic agents (e.g., SSRIs, MAO inhibitors): risk of serotonin syndrome.

Moderate Interactions (Monitor Closely): - Oral contraceptives: may reduce hormonal efficacy, consider alternative contraception. - Caffeine or other stimulants: may enhance central nervous system stimulation. - Antidepressants (e.g., bupropion): monitor for heightened side effects. - Anticoagulants (e.g., warfarin): observe INR for possible alteration.